Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade F 41.49 -2.49% -1.06
FGEN closed down 2.49 percent on Friday, September 13, 2019, on 1.79 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FGEN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -2.49%
Slingshot Bearish Bearish Swing Setup -4.47%
Crossed Above 20 DMA Bullish -4.47%
Stochastic Buy Signal Bullish -4.47%
Gapped Up Strength -4.47%
Oversold Stochastic Weakness -4.47%
Lower Bollinger Band Walk Weakness 0.46%
Lower Bollinger Band Touch Weakness 0.46%
Oversold Stochastic Weakness 0.46%
Lower Bollinger Band Touch Weakness 2.34%

Older signals for FGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Chronic Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical
Is FGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 61.95
52 Week Low 33.51
Average Volume 514,620
200-Day Moving Average 46.9944
50-Day Moving Average 44.8672
20-Day Moving Average 43.2565
10-Day Moving Average 42.073
Average True Range 1.9437
ADX 16.65
+DI 20.9684
-DI 28.7808
Chandelier Exit (Long, 3 ATRs ) 40.6689
Chandelier Exit (Short, 3 ATRs ) 45.8711
Upper Bollinger Band 46.5291
Lower Bollinger Band 39.9839
Percent B (%b) 0.23
BandWidth 15.131136
MACD Line -0.856
MACD Signal Line -0.7678
MACD Histogram -0.0882
Fundamentals Value
Market Cap 2.95 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -21.61
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.82
Resistance 3 (R3) 45.03 44.12 44.27
Resistance 2 (R2) 44.12 43.28 44.02 44.08
Resistance 1 (R1) 42.81 42.75 42.36 42.60 43.89
Pivot Point 41.90 41.90 41.68 41.80 41.90
Support 1 (S1) 40.59 41.06 40.14 40.38 39.09
Support 2 (S2) 39.68 40.53 39.58 38.90
Support 3 (S3) 38.37 39.68 38.72
Support 4 (S4) 38.16